VRAX
Virax Biolabs Group Limited Ordinary Shares
NASDAQ: VRAX · HEALTHCARE · BIOTECHNOLOGY
$0.13
-0.81% today
Updated 2026-04-30
Market cap
$993260.00
P/E ratio
—
P/S ratio
332.64x
EPS (TTM)
$-1.22
Dividend yield
—
52W range
$0 – $1
Volume
15.9M
Virax Biolabs Group Limited Ordinary Shares (VRAX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-744613.00 | $-590186.00 | $-809069.00 | $-4.18M | $-6.25M | $-4.56M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $178403.00 | $1.16M | $603890.00 |
| Depreciation | — | — | $0.00 | $0.00 | $103099.00 | $343387.00 |
| Stock-based comp | — | $0.00 | $290364.00 | $1.73M | $1.01M | $365309.00 |
| Free cash flow | $-744613.00 | $-590186.00 | $-809069.00 | $-4.36M | $-7.41M | $-5.17M |
| Investing cash flow | $-178403.00 | $-178403.00 | $-178403.00 | $-178403.00 | $-1.16M | $-603890.00 |
| Financing cash flow | $704639.00 | $585198.00 | $813205.00 | $13.69M | $1.65M | $5.81M |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |